IP Library › Granted Patent US 8,975,371
Granted Patent B2
US 8,975,371 · App. 14/086,067 · Granted Mar 10, 2015

Melanoma antigen peptide and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,371
App. No.
14/086,067
Granted
Mar 10, 2015
Kind
B2
Abstract

The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.

Claims (10)

1. A melanoma antigen peptide

having an amino acid sequence that is less than 50 amino acids in length and comprising SEQ ID NO:3:

(SEQ ID NO: 3)

RX 2 PPKPPLX 9

wherein X 2 is cysteine, leucine, methionine, valine, isoleucine or glutamine and X 9 is alanine, valine or leucine.

2. A melanoma antigen peptide according to claim 1 , wherein said melanoma antigen peptide is MELOE-2 having the sequence SEQ ID NO: 5.

3. A melanoma antigen peptide according to claim 1 , wherein said melanoma antigen peptide is selected in the group consisting of peptides having the sequence SEQ ID NO: 21 to SEQ ID NO: 38.

4. A MHC/peptide multimer comprising a melanoma antigen peptide according to claim 3 .

5. An immunising composition comprising

at least one melanoma antigen peptide according to claim 1 .

Assignments (1)
MERGER Recorded Sep 7, 2023
From: UNIVERSITE DE NANTES
To: NANTES UNIVERSITE
Reel/Frame 064824/0596 →